Semaglutide acts on GLP-1 receptors in the hypothalamusthe brain region responsible for regulating hunger and satiety signals
Haven't found what you want
Because retatrutide is not yet licensed in the UK, it is not routinely available for prescribing outside a clinical trial or a specific MHRA access scheme (such as the Early Access to Medicines Scheme [EAMS] or named-patient unlicensed supply)
The Takeaway: Could This Injectable Be Your Weight Loss Solution
Microbiota-driven gutbrain signaling underlies antidepressant effects of a GLP-1 analog by Liang Bian, Yang Cai, Yuan Zhang, Ling Shen, Huijuan Wang, Feng Gao, Ningbo Cai, Wenbo Chen, Conghui You, Yurui Yang, Fang Wang, Yonggui Yuan, Bing Han, and Honghong Yao
Generally, an individual may be a candidate for GLP-1 therapy if: They have a Body Mass Index (BMI) of 30 or higher